Lukas Scheibler's Insider Trades & SAST Disclosures

Lukas Scheibler's most recent trade in Apellis Pharmaceuticals Inc was a trade of 10,000 Common Stock done at an average price of $60 . Disclosure was reported to the exchange on Dec. 1, 2023.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Sale of securities on an exchange or to another person at price $ 60.00 per share. 01 Dec 2023 10,000 68,299 (0%) 0% 60 600,000 Common Stock
Apellis Pharmaceuticals Inc
Scheibler Lukas Chief Research Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 01 Dec 2023 10,000 78,299 (0%) 0% 13.9 138,500 Common Stock
Apellis Pharmaceuticals Inc
Scheibler Lukas Chief Research Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Dec 2023 10,000 39,391 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Feb 2023 14,023 14,023 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Feb 2023 9,886 70,358 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. 21 Feb 2023 715 69,643 (0%) 0% 58.5 41,828 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. 10 Feb 2023 678 60,472 (0%) 0% 51.2 34,720 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. 27 Jan 2023 542 61,150 (0%) 0% 52.8 28,601 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. 20 Jan 2023 2,015 61,692 (0%) 0% 52.1 104,881 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Jan 2023 35,472 35,472 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler Chief Research Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Jan 2023 22,580 63,707 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Other type of transaction at price $ 0.00 per share. 21 Apr 2022 11,250 0 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 43.00 per share. 21 Apr 2022 10,000 40,358 (0%) 0% 43 430,000 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Other type of transaction at price $ 0.00 per share. 21 Apr 2022 1,875 50,358 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 60.09 per share. 05 Apr 2022 609 52,233 (0%) 0% 60.1 36,593 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 05 Apr 2022 609 49,391 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 05 Apr 2022 609 52,842 (0%) 0% 13.9 8,435 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 04 Apr 2022 3,504 50,000 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 04 Apr 2022 3,504 55,737 (0%) 0% 13.8 48,530 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 56.86 per share. 04 Apr 2022 1,437 53,482 (0%) 0% 56.9 81,714 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 57.80 per share. 04 Apr 2022 1,249 52,233 (0%) 0% 57.8 72,198 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 55.84 per share. 04 Apr 2022 818 54,919 (0%) 0% 55.8 45,677 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 01 Apr 2022 11,496 63,729 (0%) 0% 13.9 159,220 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Apr 2022 11,496 53,504 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 55.05 per share. 01 Apr 2022 11,496 52,233 (0%) 0% 55.1 632,855 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. 14 Feb 2022 720 52,233 (0%) 0% 26.7 19,246 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Feb 2022 720 133,777 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 46.80 per share. 11 Feb 2022 1,666 51,513 (0%) 0% 46.8 77,969 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 10 Feb 2022 10,000 63,179 (0%) 0% 13.9 138,500 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 50.00 per share. 10 Feb 2022 10,000 53,179 (0%) 0% 50 500,000 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Feb 2022 10,000 65,000 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. 10 Feb 2022 678 53,179 (0%) 0% 47.1 31,947 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 08 Feb 2022 10,000 75,000 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. 08 Feb 2022 10,000 63,857 (0%) 0% 13.9 138,500 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 45.00 per share. 08 Feb 2022 10,000 53,857 (0%) 0% 45 450,000 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 38.47 per share. 28 Jan 2022 1,233 53,857 (0%) 0% 38.5 47,434 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. 28 Jan 2022 642 55,090 (0%) 0% 38.6 24,775 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Jan 2022 36,951 36,951 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Jan 2022 26,051 55,732 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. 21 Jan 2022 3,021 29,681 (0%) 0% 26.7 80,751 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jan 2022 3,021 134,497 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Sale of securities on an exchange or to another person at price $ 60.00 per share. 10 Jun 2021 3,417 26,651 (0%) 0% 60 205,020 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. 10 Feb 2021 680 29,290 (0%) 0% 47.7 32,450 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 45,000 45,000 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 11,250 11,250 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 7,500 28,095 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Jan 2021 1,875 29,970 (0%) 0% 0 Common Stock
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 08 Dec 2020 7,482 137,518 - - Stock Option (Right to Buy)
Apellis Pharmaceuticals Inc
Lukas Scheibler CHIEF INNOVATION OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.73 per share. 08 Dec 2020 7,482 20,595 (0%) 0% 26.7 199,994 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades